A Study of RO7821657 in Participants With Solid Tumors
A First In-Human, Multicenter, Phase I Clinical Study of RO7821657, a Protease Activated TCB Antibody That Targets CEACAM5, in Participants With Locally Advanced and/or Metastatic Solid Tumors
The aim of this study is to characterize the safety and tolerability of RO7821657, describe its pharmacokinetics (PK), and evaluate pharmacodynamic and biomarker effects to support selection of the recommended Phase 2 dose(s) (RP2D[s])
The study consists of two parts, namely Part 1 and Part 2:
Part 1: Evaluation of RO7821657 as monotherapy in participants with microsatellite-stable (MSS) colorectal cancer (CRC).
Part 2: Evaluation of RO7821657 as monotherapy in participants with non-squamous non-small cell lung cancer (NSCLC)
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry
研究連絡先のバックアップ
- 名前:Reference Study ID Number: BP46447 https://forpatients.roche.com/
- 電話番号:888-662-6728
- メール:global-roche-genentech-trials@gene.com
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Life expectancy estimated by the Investigator to be ≥12 weeks.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1.
- Presence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; previously irradiated lesions are considered measurable if progression has been demonstrated in such lesions after the irradiation.
- Availability of archival tumor tissue or tissue obtained from a fresh biopsy at screening if formalin-fixed paraffin-embedded [FFPE]-preserved archival tissue is not available. The archival tumor tissue should come from a core biopsy, a punch biopsy, an excisional biopsy, or a surgical specimen. Lymph node biopsy, bone biopsy (unless from soft tissue), or fine needle aspiration are unacceptable for submission. Lesions that are intended to be biopsied should not be counted as target lesions.
- Adequate cardiovascular function:
New York Heart Association (NYHA) Heart Failure Class ≤ 1.
- Agreement to adhere to the contraception requirements.
Exclusion Criteria:
-
Participants with active Central Nervous System (CNS) metastases.
-
Any unresolved toxicities from prior therapy, i.e., radiotherapy, chemotherapy, targeted or checkpoint inhibitor therapy or surgical procedure, greater than CTCAE Grade 1 at the time of starting study treatment, except for alopecia and Grade 2 neuropathy.
a) Stable endocrine AEs managed with hormone replacement are permitted, including hypothyroidism on stable thyroid hormone replacement.
-
History of interstitial pulmonary disease, drug-induced pneumonitis, or evidence of active pneumonitis on screening computed tomography (CT) scan.
-
Participants with pulmonary miliary metastatic pattern (innumerable small lesions) or pulmonary lymphangitic carcinomatosis.
-
Active autoimmune disease that has required systemic treatment (except replacement treatment) within the last 2 years or any disease requiring immunosuppressive therapy while on study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part 1A: Dose Escalation
Participants with MSS CRC will receive multiple doses of RO7821657 in single and multiple participant cohorts. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
|
実験的:Part 1B: Backfill Cohorts
Participants with MSS CRC will receive RO7821657 at dosing regimen selected based on data from Part 1A. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
|
実験的:Part 1C: Dose Expansion/Optimization
Participants with MSS CRC will receive RO7821657 at dosing regimens selected based on data from Parts 1A and 1B. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
|
実験的:Part 2A: Abbreviated Dose Escalation
Participants with non-squamous NSCLC will receive multiple doses of RO7821657 in multiple participant cohorts. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
|
実験的:Part 2B: Dose Expansion/Optimization
Participants with non-squamous NSCLC will receive RO7821657 at dosing regimen selected based on data from Part 2A. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part 1: Incidence and Severity of Adverse Events (AEs)
時間枠:Up to approximately 27 months
|
AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Any events of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded based on the American Society for Transplantation and Cellular Therapy (ASTCT) criteria |
Up to approximately 27 months
|
|
Part 2: Incidence and Severity of Adverse Events (AEs)
時間枠:Up to approximately 27 months
|
AEs will be graded according to NCI CTCAE v5.0. Any events of CRS and ICANS will be graded based on the ASTCT criteria |
Up to approximately 27 months
|
|
Part 1A: Nature and Frequency of Dose-limiting Toxicities (DLTs)
時間枠:From Cycle 1 (C1) Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
|
From Cycle 1 (C1) Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
|
|
|
Part 2A: Nature and Frequency of DLTs
時間枠:From C1 Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
|
From C1 Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
|
|
|
Parts 1A and 1B: Recommended Phase 2 Dose (RP2D) Range of RO7821657
時間枠:Up to approximately 27 months
|
Up to approximately 27 months
|
|
|
Part 2A: RP2D Range of RO7821657
時間枠:Up to approximately 27 months
|
Up to approximately 27 months
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Parts 1 and 2: Serum Concentration of RO7821657
時間枠:Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: Objective Response Rate (ORR)
時間枠:Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: Disease Control Rate (DCR)
時間枠:Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: Duration of Response (DoR)
時間枠:Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: Progression-free Survival (PFS)
時間枠:Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: PFS Rate
時間枠:At 6 months
|
At 6 months
|
|
Parts 1 and 2: Overall Survival (OS) Rate
時間枠:At 6 months
|
At 6 months
|
|
Parts 1 and 2: Correlation of Baseline Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Tumor Expression With Clinical Activity
時間枠:Up to approximately 27 months
|
Up to approximately 27 months
|
|
Part 1B: Cluster of Differentiation 8 (CD8) Expression in Tumor Tissue
時間枠:Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1C and 2B: Percentage of Participants With Presence, Frequency, Severity and Interference of Symptomatic Treatment Toxicities as Assessed by NCI Patient-reported Outcomes (PRO)-CTCAE
時間枠:Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1C and 2B: Change From Baseline in Symptomatic Treatment Toxicities as Assessed by NCI PRO-CTCAE
時間枠:Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1C and 2B: Percentage of Participants Troubled by Treatment Symptoms, as Assessed by Single Item European Organisation for Research and Treatment of Cancer Item Library 46 (EORTC IL46)
時間枠:Up to approximately 27 months
|
Up to approximately 27 months
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Clinical Trials、Hoffmann-La Roche
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- BP46447
- 2026-526150-14-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。